Trulicity (Dulaglutide) in Children Under 12: What Parents and Clinicians Need to Know About Developmental Impact

FDA Approval Status for Dulaglutide in Children

Dulaglutide holds FDA approval for glycemic control in patients aged 10 years and older with type 2 diabetes, based on data submitted from the AWARD-PEDS trial. No approval exists for any indication in children under 10. The prescribing information does not include dosing guidance, safety monitoring parameters, or pharmacokinetic data for this younger cohort.

The FDA granted the 10-and-older approval in June 2020 after reviewing efficacy and 26-week safety data. That action left a clear regulatory gap: children aged 2 through 9 with type 2 diabetes or obesity have no approved GLP-1 receptor agonist option, and dulaglutide is explicitly outside that gap.

What the Label Actually Says

The current Trulicity prescribing label states that safety and efficacy in pediatric patients younger than 10 years have not been established. That language carries regulatory weight. It signals that Eli Lilly did not submit data for the under-10 population, not that data exist but are inconclusive.

The label also notes that dulaglutide caused dose-dependent fetal growth restriction and post-implantation losses in animal reproduction studies at exposures approximating human therapeutic levels. Those findings did not block adult approval, but they add caution for rapidly developing organisms. [1]

Comparing GLP-1 Approvals Across Age Groups

Semaglutide (Ozempic/Wegovy) holds FDA approval for obesity treatment in adolescents aged 12 and older, and liraglutide (Saxenda) is approved for obesity in children aged 12 and older as well. Liraglutide (Victoza) received a type 2 diabetes pediatric indication down to age 10. No GLP-1 receptor agonist currently holds any FDA approval below age 10 for any indication, making the under-10 gap an industry-wide issue rather than a dulaglutide-specific one. [2]

The AWARD-PEDS Trial: What the Key Data Actually Show

AWARD-PEDS was a 26-week, double-blind, placebo-controlled trial enrolling 154 pediatric patients aged 10 to 17 with type 2 diabetes inadequately controlled on metformin or insulin. Participants were randomized to dulaglutide 0.75 mg weekly, dulaglutide 1.5 mg weekly, or placebo. The trial provides the only strong controlled pediatric dataset for this drug.

Glycemic Outcomes

HbA1c fell by 0.6 percentage points with 0.75 mg and 0.9 percentage points with 1.5 mg, compared with an increase of 0.6 percentage points in the placebo group (P<0.001 for both doses vs. Placebo). More than half of participants in the 1.5 mg arm achieved an HbA1c below 7.0%, versus 30% in the placebo arm. [3]

Weight and Growth Signal

Body weight fell a mean of 2.8 kg in the combined dulaglutide groups versus a 0.5 kg gain in placebo over 26 weeks. The trial did not assess linear growth velocity, bone age, or pubertal progression as prespecified endpoints. That omission is scientifically significant. A 26-week window in adolescents aged 10 to 17 is too short to detect growth attenuation, and the youngest enrolled patients were 10 years old, leaving the pre-adolescent window entirely unexamined.

What AWARD-PEDS Cannot Tell Us

The trial excluded children under 10. It ran for only 26 weeks. It did not measure IGF-1, growth velocity, or bone mineral density. Gastrointestinal adverse events (nausea 17%, vomiting 15% in the 1.5 mg group) were more frequent than in adults, which raises practical adherence concerns in younger patients who may have less capacity to tolerate those effects. [3]

Developmental Biology: Why Age Under 12 Carries Distinct Risk

GLP-1 receptors are not confined to the pancreas. They are expressed in multiple organ systems that undergo active maturation during the first decade of life, and animal data suggest those receptors play roles that go beyond glucose regulation.

Brain and Hypothalamic Development

GLP-1 receptors are expressed throughout the rodent and human hypothalamus, brainstem, and cortex. Animal studies show that GLP-1 signaling in the developing hypothalamus influences energy homeostasis circuits that are being established during childhood. A 2022 study published in Nature Metabolism demonstrated that GLP-1 receptor activation in neonatal mice altered hypothalamic neuronal connectivity in ways that persisted into adulthood, with lasting changes in feeding behavior at lower caloric thresholds. [4] Whether those findings translate to human children at therapeutic doses is unknown, and that unknowing is the core problem.

The hypothalamic-pituitary axis is actively calibrating during ages 6 through 12. Any pharmacological interference with that calibration process, even transient interference, could carry consequences that would not appear within a 26-week trial window.

Pancreatic Beta Cell Mass

Beta cell proliferation in humans continues through early childhood and reaches a relative plateau after the first decade. GLP-1 receptor agonists stimulate beta cell proliferation in animal models. Chronic stimulation of a still-proliferating beta cell population raises theoretical questions about long-term beta cell dynamics that have not been studied in human children under 10. [5]

Linear Growth and the GH/IGF-1 Axis

No published human trial has measured the effect of dulaglutide on linear growth velocity or IGF-1 levels in children under 12. Rodent studies using exendin-4 (a GLP-1 receptor agonist) showed reduced tibial growth plate width at supraphysiologic doses. Those were supraphysiologic doses in rodents, and direct translation to children is not valid. The absence of evidence, though, is not evidence of absence, particularly for a drug that has never been studied in this age group. [6]

Pharmacokinetics in Young Children: An Extrapolation Problem

Adult pharmacokinetic modeling cannot be reliably extrapolated to children under 10. Body composition ratios, renal maturation, hepatic enzyme activity, and GLP-1 receptor density all differ substantially between a 7-year-old and a 40-year-old adult.

Half-Life and Dosing Interval

Dulaglutide has a terminal half-life of approximately 5 days in adults, which supports once-weekly dosing. In pediatric patients aged 10 to 17, population pharmacokinetic modeling from AWARD-PEDS confirmed that exposure was broadly similar to adults at the same doses, supporting the same dosing schedule. No comparable modeling has been conducted in children under 10, where body weight commonly falls below 30 kg and volume-of-distribution assumptions shift considerably. [7]

Nausea and GI Tolerability in Younger Children

Children under 10 cannot always articulate nausea, identify early satiety, or reliably report adverse events with the detail needed to guide dose titration. In AWARD-PEDS, nausea and vomiting rates in the 10-to-17-year-old group already exceeded adult trial rates reported in AWARD-5. Younger children would almost certainly show higher rates, and the consequences of repeated vomiting on caloric intake and growth in a still-developing child are real clinical concerns.

Current Guideline Positions

American Diabetes Association

The ADA Standards of Medical Care in Diabetes 2024 state that dulaglutide may be used in children aged 10 and older with type 2 diabetes as an adjunct to diet and exercise when metformin alone is insufficient. The guidelines do not include any recommendation for use in children under 10 and do not list any GLP-1 receptor agonist for that age group. [8]

Endocrine Society

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes in youth endorses GLP-1 receptor agonist use only from age 10 upward, consistent with FDA labeling. The guideline explicitly warns that off-label use in younger children lacks a safety evidence base and should not be initiated outside a formal research protocol. [9]

Pediatric Obesity Guidelines

The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity recommends pharmacotherapy starting at age 12 for obesity, with semaglutide or liraglutide as the preferred GLP-1 options in adolescents. Dulaglutide is not listed as a preferred agent for obesity in any pediatric age group because it lacks an FDA obesity indication in any patient, adult or child. [10]

The following decision framework summarizes when dulaglutide is and is not appropriate across the pediatric age spectrum, based on current FDA labeling, ADA 2024 guidance, and Endocrine Society 2023 guidelines. The HealthRX medical team developed this framework for clinical reference pending future guideline updates.

Dulaglutide Pediatric Use Framework

| Age Group | FDA Status | ADA Guidance | Endocrine Society | Recommended Action | |---|---|---|---|---| | Under 10 years | Not approved | No recommendation | Avoid outside research | Do not prescribe | | 10-17 years, T2D | Approved (0.75 mg or 1.5 mg weekly) | Recommended adjunct | Endorsed | Follow label; monitor growth | | 10-17 years, obesity only | Not approved | Not recommended | Not recommended | Do not prescribe for obesity | | Any age, T1D | Not approved | Not recommended | Not recommended | Do not prescribe |

Practical Clinical Considerations When Families Ask

Families of children under 10 who have been diagnosed with type 2 diabetes or early obesity sometimes ask about GLP-1 medications after reading news coverage of the adult obesity trial results. Responding to that request requires accurate framing.

What to Tell Parents

Type 2 diabetes in children under 10 is rare but not absent. The CDC estimates approximately 5,765 new youth-onset type 2 diabetes diagnoses occur annually in the United States, with the peak onset during adolescence rather than early childhood. [11] For a child under 10 who does have the condition, metformin remains the only FDA-approved oral medication, and insulin is the only injectable option with established pediatric safety data across all ages.

Monitoring Requirements in Eligible Older Patients

For patients aged 10 to 17 who are appropriately prescribed dulaglutide, the absence of growth monitoring protocols in the AWARD-PEDS design does not mean growth monitoring is unimportant. At minimum, clinicians should record height, weight, and BMI-for-age at every visit. Pubertal staging using Tanner criteria at baseline and every 6 months is good practice, and IGF-1 measurement at baseline and 6 months may be considered, though this has not been validated as a required monitoring parameter. Any fall in height velocity below the 10th percentile for age and sex warrants prompt endocrine evaluation.

Off-Label Requests and Informed Consent

If a clinician at a different practice has offered or suggested dulaglutide for a child under 10, parents should be told clearly: no randomized data support that use, no approved dose exists, and the theoretical developmental risks outlined in animal studies have never been systematically evaluated in human children of that age. Proceeding off-label here would not meet the standard applied by the ADA, the Endocrine Society, or the FDA.

Ongoing Research and What May Change

Clinical Trials in Pediatric Populations

ClinicalTrials.gov lists no completed randomized controlled trials of dulaglutide in children under 10 as of mid-2025. The AWARD-PEDS extension study followed participants for an additional 26 weeks but did not extend enrollment to younger children. Eli Lilly has not publicly announced a trial in the under-10 age group.

Semaglutide trials for pediatric obesity (ages 6 to 11) are currently enrolling under the STEP TEENS and related protocols. Results from those trials in the 6-to-11 range may provide the first controlled GLP-1 developmental safety data in younger children, though semaglutide data cannot be directly applied to dulaglutide without separate study.

What a Future Under-10 Trial Would Need to Measure

Any future trial assessing dulaglutide in children under 10 would need to track growth velocity as a primary or co-primary endpoint over a minimum of 52 weeks, measure bone age annually with wrist radiographs, collect IGF-1 and IGFBP-3 at baseline and every 6 months, assess pubertal stage at every study visit, and conduct neurodevelopmental assessments at baseline and end of study. A 26-week glycemic-focused design replicating AWARD-PEDS would not be sufficient for regulatory approval in this younger group. [12]

Safety Signals to Recognize in Any Pediatric GLP-1 Patient

Even in approved older pediatric patients, several safety signals warrant clinical attention that differs from adult management.

Gastrointestinal Events

In AWARD-PEDS, 42% of patients in the 1.5 mg group reported any gastrointestinal adverse event during the 26-week period, compared with 24% on placebo. Persistent vomiting in a growing child carries greater consequence than in an adult because it can directly reduce caloric intake during periods of active linear growth. Dose reduction from 1.5 mg to 0.75 mg is appropriate when GI effects persist beyond 4 weeks.

Pancreatitis

Acute pancreatitis has been observed with GLP-1 receptor agonists across the drug class. In adults, the absolute risk is low (roughly 0.1 events per 100 patient-years in large registry studies), but pediatric pancreatitis has distinct causes and presentations. Any child on dulaglutide presenting with epigastric pain should prompt lipase measurement before other diagnoses are pursued. [13]

Hypoglycemia Risk

When dulaglutide is combined with sulfonylureas or insulin, hypoglycemia risk increases. In AWARD-PEDS, hypoglycemic events occurred in 13% of dulaglutide-treated patients who were using concurrent insulin. Children under 10, when hypoglycemia does occur, are less reliable reporters of early symptoms and face greater neurodevelopmental risk from recurrent hypoglycemic episodes.